Volumina Medical develops Adipearl, an injectable dermal filler designed to regenerate soft tissue for reconstructive surgery, dermatology and cosmetic indications. The company is a spin-off from EPFL, founded in 2018, and has been recognized among the TOP 100 Swiss Startups. It recently completed a successful first-in-human trial for Adipearl and reports promising early clinical data. Volumina plans to use new funding to accelerate clinical development and obtain regulatory approvals in key international markets. The team is working with Key Opinion Leaders to generate robust clinical evidence aimed at regulators and market access. The company raised a USD 21 million Series A to support these clinical and regulatory activities.

Total raised

$21M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2024